Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 23142

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Disease Site: Breast
PI: Soliman, Hatem

Clinical Trial 23177

A Phase 3, Open-Label, Randomized Study of Sonrotoclax(BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Disease Site: Chronic Leukemia (CLL, CML), Lymphoid Leukemia
PI: Saeed, Hayder

Clinical Trial 21131

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Kirtane, Kedar

Clinical Trial 22485

Disease Site: Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 21378

Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer
Disease Site: Breast
PI: Han, Heather

Clinical Trial 20530

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Disease Site: Lung
PI: Saltos, Andreas

Clinical Trial 21450

A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Disease Site: Acute Leukemia (ALL, AML), Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 20752

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
Disease Site: Other Digestive Organ, Other Endocrine System
PI: Strosberg, Jonathan

Clinical Trial 21721

A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib and Tafasitamab as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 22078

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Disease Site: Brain and Nervous System
PI: Grogan, Patrick